Looks at a study showing that aggressive treatment of localized low grade prostate cancer is inappropriate. Statistics related to the study; Comments regarding the study from Peter Albertsen, professor and chief of urology at the University of Connecticut Health Center; Albertsen's view that men ...
For men with "low-risk" prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment, reports a study inThe Journal of Urology, an Official Journal of the American Urological Association (AUA...
screening to see if cancer is present is still important. If the doctor suspects cancer, then he may decide to proceed with a prostate biopsy. We recognize that not all patients need to be treated if they have prostate cancer. For example, an elderly patient...
but which of these risk factors cause a prostate cell to become cancerous is not fully known. For a cancer to develop, changes must occur in the chemicals that make up the DNA, which makes up the genes in the cell. The genes control how the cell ...
(for example, 3 + 4) and is referred to as the Gleason Score. This characterizes the appearance of the cancer cells and helps predict its likely level of aggressiveness in the body. A Gleason score of 6 or less indicates a low grade prostate cancer, whereas scores of 8-10 indicate a ...
CONCLUSION: In this study population, men with prostate cancer having biopsy Gleason score 7 and tertiary grade 5 had a higher risk of PSA-failure when compared with men with Gleason score 7 without tertiary grade 5 and had a comparable risk with men with Gleason score 8 to 10. 展开 ...
BackgroundThe 2 primary therapeutic interventions for localized prostate cancer are delivered by different types of physicians, urologists, and radiation
Implementation consideration: For TaG1/low-grade tumors, even if there is no muscle tissue in the first resected specimen, a repeat TURBT is not an obligated choice. Evidence summary: We referred to the recommendations from a relevant systematic review, guidelines and monographs. (1) A systemati...
(NCCN) notes that a DRE should not be used as a stand-alone test for detection of prostate cancer but should be performed in men with an elevated PSA. The NCCN also notes that DRE may be considered as a baseline test in all patients, as it may help identify high-grade cancers ...
There are currently a number of possible management options for both low-risk and high-risk prostate cancer, and a management decision should ideally be made following input from a multidisciplinary team that includes urologists, oncologists, radiologists, pathologists, nurse specialists, and pharmacists...